Adenovirus	0	10	B-Organism
-	10	11	O
mediated	11	19	O
gene	20	24	O
transfer	25	33	O
of	34	36	O
endostatin	37	47	B-Gene_or_gene_product
in	48	50	O
vivo	51	55	O
results	56	63	O
in	64	66	O
high	67	71	O
level	72	77	O
of	78	80	O
transgene	81	90	O
expression	91	101	O
and	102	105	O
inhibition	106	116	O
of	117	119	O
tumor	120	125	B-Pathological_formation
growth	126	132	O
and	133	136	O
metastases	137	147	O
.	147	148	O

Inhibition	150	160	O
of	161	163	O
angiogenesis	164	176	O
has	177	180	O
been	181	185	O
shown	186	191	O
to	192	194	O
be	195	197	O
an	198	200	O
effective	201	210	O
strategy	211	219	O
in	220	222	O
cancer	223	229	B-Pathological_formation
therapy	230	237	O
in	238	240	O
mice	241	245	B-Organism
.	245	246	O

However	247	254	O
,	254	255	O
its	256	259	O
widespread	260	270	O
application	271	282	O
has	283	286	O
been	287	291	O
hampered	292	300	O
by	301	303	O
difficulties	304	316	O
in	317	319	O
the	320	323	O
large	324	329	O
-	329	330	O
scale	330	335	O
production	336	346	O
of	347	349	O
the	350	353	O
antiangiogenic	354	368	O
proteins	369	377	O
.	377	378	O

This	379	383	O
limitation	384	394	O
may	395	398	O
be	399	401	O
resolved	402	410	O
by	411	413	O
in	414	416	O
vivo	417	421	O
delivery	422	430	O
and	431	434	O
expression	435	445	O
of	446	448	O
the	449	452	O
antiangiogenic	453	467	O
genes	468	473	O
.	473	474	O

We	475	477	O
have	478	482	O
constructed	483	494	O
a	495	496	O
recombinant	497	508	O
adenovirus	509	519	B-Organism
that	520	524	O
expresses	525	534	O
murine	535	541	B-Organism
endostatin	542	552	B-Gene_or_gene_product
that	553	557	O
is	558	560	O
biologically	561	573	O
active	574	580	O
both	581	585	O
in	586	588	O
vitro	589	594	O
,	594	595	O
as	596	598	O
determined	599	609	O
in	610	612	O
endothelial	613	624	B-Cell
cell	625	629	I-Cell
proliferation	630	643	O
assays	644	650	O
,	650	651	O
and	652	655	O
in	656	658	O
vivo	659	663	O
,	663	664	O
by	665	667	O
suppression	668	679	O
of	680	682	O
angiogenesis	683	695	O
induced	696	703	O
by	704	706	O
vascular	707	715	B-Gene_or_gene_product
endothelial	716	727	I-Gene_or_gene_product
growth	728	734	I-Gene_or_gene_product
factor	735	741	I-Gene_or_gene_product
165	742	745	I-Gene_or_gene_product
.	745	746	O

Persistent	747	757	O
high	758	762	O
serum	763	768	B-Organism_substance
levels	769	775	O
of	776	778	O
endostatin	779	789	B-Gene_or_gene_product
(	790	791	O
605	791	794	O
-	794	795	O
1740	795	799	O
ng	800	802	O
/	802	803	O
ml	803	805	O
;	805	806	O
mean	807	811	O
,	811	812	O
936	813	816	O
ng	817	819	O
/	819	820	O
ml	820	822	O
)	822	823	O
were	824	828	O
achieved	829	837	O
after	838	843	O
systemic	844	852	O
administration	853	867	O
of	868	870	O
the	871	874	O
vector	875	881	O
to	882	884	O
nude	885	889	B-Organism
mice	890	894	I-Organism
,	894	895	O
which	896	901	O
resulted	902	910	O
in	911	913	O
significant	914	925	O
reduction	926	935	O
of	936	938	O
the	939	942	O
growth	943	949	O
rates	950	955	O
and	956	959	O
the	960	963	O
volumes	964	971	O
of	972	974	O
JC	975	977	B-Pathological_formation
breast	978	984	I-Pathological_formation
carcinoma	985	994	I-Pathological_formation
and	995	998	O
Lewis	999	1004	B-Pathological_formation
lung	1005	1009	I-Pathological_formation
carcinoma	1010	1019	I-Pathological_formation
(	1020	1021	O
P	1021	1022	O
less	1024	1028	O
than	1029	1033	O
0	1035	1036	O
.	1036	1037	O
001	1037	1040	O
and	1041	1044	O
P	1045	1046	O
less	1048	1052	O
than	1053	1057	O
0	1059	1060	O
.	1060	1061	O
05	1061	1063	O
,	1063	1064	O
respectively	1065	1077	O
)	1077	1078	O
.	1078	1079	O

In	1080	1082	O
addition	1083	1091	O
,	1091	1092	O
the	1093	1096	O
endostatin	1097	1107	B-Gene_or_gene_product
vector	1108	1114	O
treatment	1115	1124	O
completely	1125	1135	O
prevented	1136	1145	O
the	1146	1149	O
formation	1150	1159	O
of	1160	1162	O
pulmonary	1163	1172	B-Pathological_formation
micrometastases	1173	1188	I-Pathological_formation
in	1189	1191	O
Lewis	1192	1197	B-Pathological_formation
lung	1198	1202	I-Pathological_formation
carcinoma	1203	1212	I-Pathological_formation
(	1213	1214	O
P	1214	1215	O
=	1216	1217	O
0	1218	1219	O
.	1219	1220	O
0001	1220	1224	O
)	1224	1225	O
.	1225	1226	O

Immunohistochemical	1227	1246	O
staining	1247	1255	O
of	1256	1258	O
the	1259	1262	O
tumors	1263	1269	B-Pathological_formation
demonstrated	1270	1282	O
a	1283	1284	O
decreased	1285	1294	O
number	1295	1301	O
of	1302	1304	O
blood	1305	1310	B-Multi-tissue_structure
vessels	1311	1318	I-Multi-tissue_structure
in	1319	1321	O
the	1322	1325	O
treatment	1326	1335	O
group	1336	1341	O
versus	1342	1348	O
the	1349	1352	O
controls	1353	1361	O
.	1361	1362	O

In	1363	1365	O
conclusion	1366	1376	O
,	1376	1377	O
the	1378	1381	O
present	1382	1389	O
study	1390	1395	O
clearly	1396	1403	O
demonstrates	1404	1416	O
the	1417	1420	O
potential	1421	1430	O
of	1431	1433	O
vector	1434	1440	O
-	1440	1441	O
mediated	1441	1449	O
antiangiogenic	1450	1464	O
gene	1465	1469	O
therapy	1470	1477	O
as	1478	1480	O
a	1481	1482	O
component	1483	1492	O
in	1493	1495	O
cancer	1496	1502	B-Pathological_formation
therapy	1503	1510	O
.	1510	1511	O

